|
Lung cancer is the leading cause of cancer deaths among men
and women, according to the American Cancer Society (ACS). The ACS
estimates that 174,470 new cases of lung cancer will be diagnosed
in the United States in 2006, and an estimated 162,460 deaths will
result from the disease.
Completed TELCYTA non-small cell lung cancer clinical trials include:
ASSIST-2 (Assessment of Survival In
Solid Tumors-2): Phase 3 Randomized Study of TELCYTA
(TLK286) Versus Gefitinib as Third-Line Therapy in Locally Advanced
or Metastatic Non-Small Cell Lung Cancer.
Phase 2 Study of TELCYTA (TLK286) in Combination with Carboplatin and Paclitaxel as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Phase 2 Study of TELCYTA (TLK286) in Combination with Cisplatin
as First-Line Therapy in Locally Advanced or Metastatic Non-Small
Cell Lung Cancer.
Phase 2 Study of TELCYTA (TLK286) in Combination with Docetaxel
in Platinum-Resistant Non-Small Cell Lung Cancer.
Additional information about lung cancer may be found at:
Lung Cancer Alliance
|
